Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: Results of the TIMI 31 trial

Tarih
2006
Yazar
de Winter, Jobst
Murphy, Sabina A.
McCabe, Carolyn H.
Gibson, C. Michael
Zorkun, Cafer
Molhoek, Peter
Zmudka, Krzysztof
Greenberg, Mark
Mueller, Hiltrud
Wesdorp, Jan
Louwerenburg, Hans
Niederman, Alan
Westenburg, Jaap
Bikkina, Mahesh
Batty, John
Üst veri
Tüm öğe kaydını göster
Özet
Background: Currently available fibrinolytic agents are limited by their ability to restore normal blood flow in only half of patients, the risk of reocclusion, and the risk of intracranial hemorrhage. The genetically engineered agent BB-10153 is activated by thrombin, not plasminogen activator enzymes, which limits its activity to the site of thrombus which may in turn reduce the risk of systemic bleeding. BB-10153 also has a relatively long half-life of 3-4 hours, which may also limit the potential for early reocclusion [1, 2].
Bağlantı
http://hdl.handle.net/20.500.12627/181019
https://doi.org/10.1007/s11239-006-8080-1
Koleksiyonlar